Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-16 | Peter Paradiso, Ph.D. Dr. Peter R. Paradiso was appointed to our Board in September 2020. ... The Board believes that Dr. Paradiso’s extensive experience in vaccine development can provide significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to be nominated as a director. ... The following table shows for the fiscal year ended December 31, 2020, certain information with respect to the cash compensation of all non-employee directors of the Company: ... Peter R. Paradiso Fees Earned or Paid in Cash $10,769, Option Awards $157,580, Total $168,349. |
| 2022-04-14 | Dr. Paradiso has been a member of our Board since September 2020. Dr. Paradiso has worked in vaccine development for over 30 years... He is Chairman of a Procurement Reference Group (PRG) to advise The United Nations Children's Fund (UNICEF) and The GAVI Alliance... We believe that Dr. Paradiso’s extensive experience in vaccine development can provide significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to serve as a director. |
| 2023-04-13 | Peter R. Paradiso, Ph.D. Dr. Paradiso has been a member of our Board since September 2020. ... Our Board believes that Dr. Paradiso’s extensive experience in vaccine development can provide significant insights and qualifies him to serve on our Board. |
| 2024-04-11 | Peter R. Paradiso, Ph.D. Dr. Paradiso has been a member of our Board since September 2020. ... Our Board believes that Dr. Paradisos extensive experience in vaccine development can provide significant insights and qualifies him to be nominated as a director. |
Data sourced from SEC filings. Last updated: 2026-03-05